(VIANEWS) – Crown Castle International (CCI), Mid (MAA), Lancaster Colony Corporation (LANC) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio so far. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Crown Castle International (CCI)
156.87% Payout Ratio
Crown Castle owns, operates and leases more than 40,000 cell towers and approximately 85,000 route miles of fiber supporting small cells and fiber solutions across every major U.S. market. This nationwide portfolio of communications infrastructure connects cities and communities to essential data, technology and wireless service – bringing information, ideas and innovations to the people and businesses that need them.
Earnings Per Share
As for profitability, Crown Castle International has a trailing twelve months EPS of $3.93.
PE Ratio
Crown Castle International has a trailing twelve months price to earnings ratio of 26.61. Meaning, the purchaser of the share is investing $26.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.9%.
Moving Average
Crown Castle International’s value is below its 50-day moving average of $110.39 and way under its 200-day moving average of $126.94.
Volume
Today’s last reported volume for Crown Castle International is 871747 which is 71.56% below its average volume of 3065970.
2. Mid (MAA)
103.52% Payout Ratio
MAA, an S&P 500 company, is a real estate investment trust (REIT) focused on delivering full-cycle and superior investment performance for shareholders through the ownership, management, acquisition, development and redevelopment of quality apartment communities primarily in the Southeast, Southwest and Mid-Atlantic regions of the United States. As of June 30, 2023, MAA had ownership interest in 101,986 apartment units, including communities currently in development, across 16 states and the District of Columbia.
Earnings Per Share
As for profitability, Mid has a trailing twelve months EPS of $5.12.
PE Ratio
Mid has a trailing twelve months price to earnings ratio of 28.17. Meaning, the purchaser of the share is investing $28.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.81%.
3. Lancaster Colony Corporation (LANC)
69.33% Payout Ratio
Lancaster Colony Corporation manufactures and markets food products for the retail and foodservice markets in the United States. The company operates in two segments, Retail and Foodservice. It offers frozen garlic bread under the New York BRAND Bakery; frozen Parkerhouse style yeast and dinner rolls under the Sister Schubert's brand; salad dressings under the Marzetti, Cardini's, and Girard's; flatbread wraps and pizza crusts under the Flatout brand; croutons and salad toppings under the New York BRAND Bakery, Chatham Village, and Marzetti; frozen pasta under the Marzetti Frozen Pasta brand; and vegetable and fruit dips under the Marzetti brand. In addition, it manufactures and sells other products to brand license agreements, including Olive Garden dressings, Buffalo Wild Wings sauces and Chick-fil-A sauces. The company sells its products through sales personnel, food brokers, and distributors to retailers and restaurants. Lancaster Colony Corporation was incorporated in 1961 and is based in Westerville, Ohio.
Earnings Per Share
As for profitability, Lancaster Colony Corporation has a trailing twelve months EPS of $4.76.
PE Ratio
Lancaster Colony Corporation has a trailing twelve months price to earnings ratio of 40.61. Meaning, the purchaser of the share is investing $40.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.32%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Lancaster Colony Corporation’s EBITDA is 127.86.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.2%, now sitting on 1.82B for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 7, 2023, the estimated forward annual dividend rate is 3.4 and the estimated forward annual dividend yield is 1.75%.
Yearly Top and Bottom Value
Lancaster Colony Corporation’s stock is valued at $193.32 at 08:23 EST, way below its 52-week high of $220.65 and way above its 52-week low of $138.49.
4. Main Street Capital Corporation (MAIN)
69.17% Payout Ratio
Main Street Capital Corporation is a principal investment firm that primarily provides equity capital to lower middle market companies and debt capital to middle market companies. Main Street's portfolio investments are typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides "one stop" financing alternatives within its lower middle market portfolio. Main Street's lower middle market companies generally have annual revenues between $10 million and $150 million. Main Street's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies.
Earnings Per Share
As for profitability, Main Street Capital Corporation has a trailing twelve months EPS of $3.33.
PE Ratio
Main Street Capital Corporation has a trailing twelve months price to earnings ratio of 12.16. Meaning, the purchaser of the share is investing $12.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.88%.
5. Pfizer (PFE)
43.09% Payout Ratio
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Pfizer has a trailing twelve months EPS of $5.07.
PE Ratio
Pfizer has a trailing twelve months price to earnings ratio of 7.11. Meaning, the purchaser of the share is investing $7.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.07%.
Volume
Today’s last reported volume for Pfizer is 6672210 which is 75.48% below its average volume of 27216700.
Previous days news about Pfizer (PFE)
- The zacks analyst blog highlights broadcom, Pfizer, advanced micro devices, charles schwab, canadian national railway and d.r. horton. According to Zacks on Thursday, 17 August, "Stocks recently featured in the blog include: Broadcom Inc. (AVGO Quick QuoteAVGO – Free Report) , Pfizer Inc. (PFE Quick QuotePFE – Free Report) , Advanced Micro Devices, Inc. (AMD Quick QuoteAMD – Free Report) , The Charles Schwab Corporation (SCHW Quick QuoteSCHW – Free Report) , Canadian National Railway Company (CNI Quick QuoteCNI – Free Report) and D.R. Horton, Inc. (DHI Quick QuoteDHI – Free Report) .", "Today’s Research Daily features new research reports on 16 major stocks, including Broadcom Inc., Pfizer Inc. and Advanced Micro Devices, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today."
- According to Zacks on Thursday, 17 August, "Aquipta likely holds an edge over the Pfizer and Eli Lilly drugs since it is the currently the only oral drug approved for the prevention of episodic and chronic migraine. "
- According to MarketWatch on Thursday, 17 August, "Moderna shares jumped 7.4%, while BioNTech’s ADR climbed 4.9%, Novavax Inc. shares gained 3.4%, and Pfizer Inc. stock rose 2.9%."
- According to Zacks on Friday, 18 August, "In the past six months, Lilly has risen the most (63.7%), while Pfizer has declined the most (15.5%)."
- According to Zacks on Friday, 18 August, "Apart from Moderna, other COVID vaccine makers like Pfizer (PFE Quick QuotePFE – Free Report) /BioNTech (BNTX Quick QuoteBNTX – Free Report) and Novavax (NVAX Quick QuoteNVAX – Free Report) have also updated their own vaccines to target the XBB lineages. ", "In June, Pfizer and BioNTech submitted filings in Europe and the United States seeking approval for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. "
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
